<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14029">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343915</url>
  </required_header>
  <id_info>
    <org_study_id>101695 Ext. Mth30</org_study_id>
    <secondary_id>101696</secondary_id>
    <secondary_id>101697</secondary_id>
    <secondary_id>101698</secondary_id>
    <nct_id>NCT00343915</nct_id>
    <nct_alias>NCT00787228</nct_alias>
  </id_info>
  <brief_title>Immuno &amp; Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs</brief_title>
  <official_title>Long-term Study of Immune Response Persistence of GSK Biologicals' 2-dose Thiomersal-free Engerix™-B and 3-dose Preservative-free Engerix™-B Vaccines in Subjects Aged 11-15 Yrs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the persistence of antibodies against hepatitis B at 30, 42, 54 and 66 months
      after the first dose of the hepatitis B primary vaccination course.

      Subjects were aged 11 to 15 years at the time of the primary vaccination course.

      At the time of enrollment in the present long-term follow-up study subjects were aged 13 to
      18 years.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects who participated in the primary study, in which they received either 2 or 3
      doses of GSK Biologicals hepatitis B vaccine, and who consented to participate in the
      long-term follow-up at Month 42 were contacted by the investigators.

      No additional subjects will be recruited during this long-term follow-up study and no
      vaccine will be administered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Anti-hepatitis B Surface Antigen (Anti-HBs) Seroprotected Subjects</measure>
    <time_frame>At Months 30, 42, 54 &amp; 66</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of seroprotected subjects (i.e. with anti-HBs antibody concentrations ≥ 10 mIU/ml) is given for each respective follow-up timepoint.
The total number of subjects analysed (N) is given for both groups between brackets in the category titles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Serious Adverse Events Determined by the Investigators to Have a Causal Relationship to Vaccination or to Study Procedures</measure>
    <time_frame>At Months 30, 42, 54 &amp; 66</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>2-Dose Engerix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-Dose Engerix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix™-B (thiomersal-free) 20µg</intervention_name>
    <description>In the primary study: 2 deep intramuscular injections (Months 0, &amp; 6)</description>
    <arm_group_label>2-Dose Engerix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10 μg Engerix™-B (preservative-free)</intervention_name>
    <description>In the primary study: 3 deep intramuscular injections (months 0, 1 &amp; 6)</description>
    <arm_group_label>3-Dose Engerix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>In the primary study: 1 deep intramuscular injection (month 1)</description>
    <arm_group_label>2-Dose Engerix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects have participated in primary study HBV-280

          -  Written informed consent will be obtained from each subject and/ or parent or
             guardian of the subject before the blood-sampling visit of each year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Ukraine</country>
  </location_countries>
  <reference>
    <citation>Heron LG et al. A novel hepatitis B vaccination regimen for adolescents - 2 doses 12 months apart. Abstract presented at the 10th ICID Singapore, Bangkok, March 2002.</citation>
  </reference>
  <reference>
    <citation>Heron L, Selnikova O, Moiseieva A, Van Damme P, van der Wielen M, Levie K, Hoet B, Stoffel M. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial. Vaccine. 2007 Apr 12;25(15):2817-22. Epub 2006 Dec 29.</citation>
    <PMID>17276552</PMID>
  </reference>
  <reference>
    <citation>Heron L et al. Randomised control trial: 2-vs 3-dose hepatitis B immunization of adolescents. Abstract presented at the 12th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD), Paris, France, 1-5 July 2006.</citation>
  </reference>
  <reference>
    <citation>Van Damme P, Moiseeva A, Marichev I, Kervyn AD, Booy R, Kuriyakose S, Brockway A, Ng SP, Leyssen M, Jacquet JM. Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. BMC Infect Dis. 2010 Dec 20;10:357. doi: 10.1186/1471-2334-10-357.</citation>
    <PMID>21171982</PMID>
  </reference>
  <reference>
    <citation>Heron LG, Chant KG, Jalaludin BB. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine. 2002 Oct 4;20(29-30):3472-6.</citation>
    <PMID>12297392</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>October 2, 2014</lastchanged_date>
  <firstreceived_date>September 14, 2005</firstreceived_date>
  <firstreceived_results_date>December 23, 2008</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistence</keyword>
  <keyword>Hepatitis B vaccine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects who participated in the primary vaccination study, in which they received either 2 or 3 doses of GSK Biologicals hepatitis B vaccine, and who consented to participate in the long-term follow-up were contacted by the investigators.
No additional subjects were recruited during this long-term follow-up study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>2-dose Engerix</title>
          <description>subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.</description>
        </group>
        <group group_id="P2">
          <title>3-dose Engerix</title>
          <description>subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Month 30 Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="179">Subjects, previously vaccinated, that returned for the Month 30 follow-up.</participants>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Month 42 Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="174">Subjects, previously vaccinated, that returned for the Month 42 follow-up.</participants>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Month 54 Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166">Subjects, previously vaccinated, that returned for the Month 54 follow-up.</participants>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Month 66 Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="158">Subjects, previously vaccinated, that returned for the Month 66 follow-up.</participants>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2-dose Engerix</title>
          <description>subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.</description>
        </group>
        <group group_id="B2">
          <title>3-dose Engerix</title>
          <description>subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="179"/>
                <measurement group_id="B2" value="88"/>
                <measurement group_id="B3" value="267"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15.6" spread="1.34"/>
                <measurement group_id="B2" value="15.4" spread="1.59"/>
                <measurement group_id="B3" value="15.5" spread="1.43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="92"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="136"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="87"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="131"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Anti-hepatitis B Surface Antigen (Anti-HBs) Seroprotected Subjects</title>
        <description>The number of seroprotected subjects (i.e. with anti-HBs antibody concentrations ≥ 10 mIU/ml) is given for each respective follow-up timepoint.
The total number of subjects analysed (N) is given for both groups between brackets in the category titles.</description>
        <time_frame>At Months 30, 42, 54 &amp; 66</time_frame>
        <safety_issue>No</safety_issue>
        <population>Long Term According-to-Protocol cohort for immunogenicity, including all subjects who returned at the considered follow-up time point and who complied with the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>2-dose Engerix</title>
            <description>subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.</description>
          </group>
          <group group_id="O2">
            <title>3-dose Engerix</title>
            <description>subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="179"/>
                  <measurement group_id="O2" value="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Anti-hepatitis B Surface Antigen (Anti-HBs) Seroprotected Subjects</title>
            <description>The number of seroprotected subjects (i.e. with anti-HBs antibody concentrations ≥ 10 mIU/ml) is given for each respective follow-up timepoint.
The total number of subjects analysed (N) is given for both groups between brackets in the category titles.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Month 30 (N1=140,N2=64)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="122"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 42 (N1=166,N2=80)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="139"/>
                  <measurement group_id="O2" value="74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 54 (N1=147,N2=76)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 66 (N1=132,N2=70)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Serious Adverse Events Determined by the Investigators to Have a Causal Relationship to Vaccination or to Study Procedures</title>
        <time_frame>At Months 30, 42, 54 &amp; 66</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>2-dose Engerix</title>
            <description>subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.</description>
          </group>
          <group group_id="O2">
            <title>3-dose Engerix</title>
            <description>subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="179"/>
                  <measurement group_id="O2" value="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Occurrence of Serious Adverse Events Determined by the Investigators to Have a Causal Relationship to Vaccination or to Study Procedures</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Non-serious adverse events were not assessed during this long term follow-up study.</desc>
      <group_list>
        <group group_id="E1">
          <title>2-dose Engerix</title>
          <description>subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.</description>
        </group>
        <group group_id="E2">
          <title>3-dose Engerix</title>
          <description>subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
